A composition for improving intestinal function, its preparation method, application and product thereof.

By combining PHGG with resistant dextrin in a specific ratio and using a granulation process, the problem of incomplete intestinal function regulation in existing technologies has been solved. This achieves dual intervention of intestinal flora and physiological function, significantly improving constipation and diarrhea, and is applicable to the food, health product and pharmaceutical fields.

CN123100828APending Publication Date: 2026-11-17COMFORT MEDICAL FOOD (ZHENGZHOU) CO LTD +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202611585127.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies cannot simultaneously address multiple functions such as gut microbiota regulation and intestinal barrier protection, and PHGG alone is significantly insufficient in improving constipation and diarrhea.

Method used

PHGG is compounded with resistant dextrin in a specific ratio to form a fully soluble dietary fiber composition. The solubility is improved through mixing and granulation processes, and various dosage forms are made for use in food, health products or pharmaceuticals.

Benefits of technology

It achieves bidirectional regulation of intestinal function, synergistically improves diarrhea and constipation, avoids the risk of intestinal obstruction caused by insoluble fiber, has a wide range of applications, and is simple and easy to industrialize.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_15
    Figure SMS_15
  • Figure SMS_16
    Figure SMS_16
Patent Text Reader

Abstract

This invention, entitled "A Composition for Improving Intestinal Function, Its Preparation Method, Applications, and Products," belongs to the fields of food, special dietary foods, and pharmaceutical technology. The technical problem it aims to solve is that existing technologies, using only single dietary fibers or prebiotics, struggle to simultaneously achieve multiple benefits, including efficient regulation of gut microbiota, bidirectional regulation of diarrhea and constipation, and maintenance of intestinal barrier integrity. Therefore, this invention provides a composition with synergistic effects on gut health. The key technical point is a composition for improving intestinal function, composed of galactomannan and resistant dextrin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of food, special dietary foods and pharmaceutical technology, specifically to a composition for improving intestinal function, its preparation method, application and products. Background Technology

[0002] In modern society, due to factors such as changes in dietary structure, increased mental stress, and population aging, problems such as intestinal dysfunction (e.g., diarrhea, constipation) are becoming increasingly common. Dietary fiber, due to its important role in maintaining intestinal health, has become a hot topic in the research and development of functional foods and drugs.

[0003] Galactomannan (PHGG), a partially hydrolyzed product of guar gum, is a 100% water-soluble dietary fiber with extremely high fermentability. Studies have shown that PHGG fermentation by gut microbiota can produce a large amount of short-chain fatty acids (SCFAs, especially butyrate). These are not only the main energy source for colonic epithelial cells but also promote epithelial cell differentiation, tight junction protein expression, and mucus secretion, thereby maintaining intestinal barrier function. Furthermore, the acidic environment created by PHGG fermentation helps inhibit the growth of harmful bacteria and promotes the growth of probiotics; clinical studies have confirmed its ameliorative effect on enteral nutrition-associated diarrhea in critically ill patients. However, PHGG has a significant drawback in practical applications: poor solubility, especially prone to clumping in cold water, affecting its dispersion uniformity in various formulations and user experience.

[0004] Resistant dextrin is another high-quality water-soluble dietary fiber with excellent solubility, heat stability, and pH stability. It not only acts as a prebiotic to selectively promote the proliferation of probiotics, but also achieves "two-way regulation" by adjusting the water content and volume of intestinal contents: on the one hand, it absorbs excess water in the intestines to relieve diarrhea, and on the other hand, it relieves constipation by softening stool and increasing stool volume.

[0005] Currently, while there are studies on the use of PHGG or resistant dextrin alone, no reported technical solutions have been developed that combine the two to address the solubility issue of PHGG and synergistically exert both "microbiota regulation" and "intestinal physiological regulation" effects. Furthermore, for critically ill patients and other special populations, insoluble fiber may pose risks such as intestinal obstruction, and the advantages of fully soluble fiber combinations urgently need to be explored. Therefore, developing a composition that combines excellent solubility with the ability to bidirectionally regulate intestinal function and immunity is of great significance.

[0006] Relevant patent documents retrieved: This document, published in China (CN122140755A) on June 5, 2026, discloses a composition comprising the following components: resistant dextrin, partially hydrolyzed guar gum (PHGG), polydextrose, and β-glucan. Furthermore, the document verifies the efficacy of a combination of oat β-glucan and yeast β-glucan, demonstrating significant therapeutic effects in improving IBS and IBD in subjects. In some embodiments, the composition comprises the following components: resistant dextrin, PHGG, polydextrose, oat β-glucan, and yeast β-glucan.

[0007] This document, published in China (CN116473243A) on July 25, 2023, discloses a dietary fiber composition comprising the following ingredients in parts by weight: 0.84-1.68 parts by weight of gum arabic, 0.6-1.2 parts by weight of galactomannan, 0.6-1.2 parts by weight of oat β-glucan, 0.24-0.48 parts by weight of resistant dextrin, and 0.12-0.24 parts by weight of stachyose. This dietary fiber composition is said to have the effects of lowering blood sugar, lowering insulin, lowering glucagon (GC), improving insulin sensitivity (QUICKI) and insulin resistance index (HOMA-IR) caused by diabetes, reducing liver triglyceride accumulation, reducing subcutaneous fat cell size, and lowering high cholesterol and low-density lipoprotein levels.

[0008] This document, published in China (CN121337013A) on January 16, 2026, discloses an immunomodulatory prebiotic syrup synergistic with galactomannan. Its active ingredients are composed of the following ingredients by weight percentage: fructooligosaccharides 20%-35%, galacto-oligosaccharides 10%-18%, stachyose 8%-15%, xylooligosaccharides 3%-7%, lactitol 5%-12%, galactomannan 5%-10%, yeast β-glucan 2%-5%, and N-acetylglucosamine 1%-3%. The composition further includes inulin and resistant dextrin as a matrix filler and sustained-release carrier, with inulin content at 4%-8% and resistant dextrin content at 3%-6%. The sum of the weight percentages of all active ingredients and the carrier is 100%. By reshaping the intestinal microecology and inhibiting inflammatory pathways, it can significantly improve intestinal inflammation and promote the expression of tight junction proteins in the intestinal mucosa, providing an innovative solution for people with chronic intestinal diseases and immune imbalances.

[0009] This document, published in China (CN122536689A) on August 11, 2026, discloses a stachyose-rich strontium-enriched water composition for regulating intestinal flora balance and its preparation method. The composition comprises stachyose, strontium-enriched water, fructooligosaccharides, resistant dextrin, inulin, galactomannan, and apple pectin. The preparation method includes steps such as strontium-enriched water degassing pretreatment, pectin solution preparation, compound prebiotic slurry preparation, calcium chloride-induced formation of calcium pectate microencapsulation precursor, and homogenization compounding. This document, through the scientific combination of multiple prebiotics and strontium-enriched water, combined with a unique calcium pectate microencapsulation precursor process, significantly improves the product's physical stability and colon-targeted delivery performance of prebiotics. Experiments show that the composition of the present invention can effectively promote the proliferation of Bifidobacteria and Lactobacillus, inhibit the growth of Enterococcus and Enterobacter, significantly increase the content of short-chain fatty acids such as butyric acid in the intestine, and has good storage stability and safety. It can be used as a medicine, dietary supplement or functional beverage in the field of intestinal health.

[0010] This document, published in China (CN121621519A) on March 10, 2026, discloses a composition that combines the effects of rapidly acting plant extracts and long-term probiotics, and its uses. The composition comprises a rapidly acting first composition, further comprising plant extracts, and a long-term effect second composition, further comprising one or more of probiotics, prebiotics, and post-biotics. The first and second compositions work synergistically to improve digestive system function, strengthen the intestinal barrier, enhance immunity, improve mood, relieve stress and anxiety, improve women's health, alleviate menopausal symptoms, improve menstrual discomfort, control and manage weight, and improve oral health.

[0011] The prior art represented by the aforementioned documents has at least the following unresolved technical problems or defects: It can only improve constipation to a limited extent and cannot simultaneously achieve multiple effects such as intestinal flora regulation and intestinal barrier protection. The relevant evidence is that in the test examples of the present invention, the single PHGG group showed in both animal models and human trials that the effect of single PHGG in increasing the frequency of spontaneous defecation, improving stool characteristics, and reducing the difficulty of defecation was significantly weaker than that of the compound composition of PHGG and resistant dextrin of the present invention. Summary of the Invention

[0012] The purpose of this invention is to provide: A composition for improving intestinal function, and related technologies thereof, to solve technical problems such as improving intestinal function, improving diarrhea, relieving constipation, or combinations thereof.

[0013] Terminology Explanation: Unless otherwise defined, all technical terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this subject matter pertains. Unless otherwise stated, all patents, patent inventions, and disclosures cited throughout this document are incorporated herein by reference in their entirety. Where multiple definitions exist for terms herein, the definitions provided in this chapter shall prevail.

[0014] It should be understood that the above brief description and the following detailed description are exemplary and for illustrative purposes only, and do not limit the subject matter of the invention in any way. In this invention, the singular is used in conjunction with the plural unless otherwise specifically stated. It should also be noted that, unless otherwise stated, the use of “or” or “or” means “and / or”. Furthermore, the use of the term “comprising” and other forms such as “including,” “containing,” and “contains” are not limiting.

[0015] Definitions of the standard terminology can be found in the references *Food Chemistry (4th Edition)* (edited by Kan Jianquan, China Agricultural University Press, 2019) and *Prebiotic Science and Technology* (edited by Jiang Zhengqiang, Science Press, 2021).

[0016] Unless otherwise stated, conventional methods within the scope of the art, such as physicochemical index detection, in vitro simulated intestinal fermentation experiments, probiotic proliferation evaluation, in vivo intestinal function evaluation in animals, and dietary fiber component determination, shall be used.

[0017] Unless specifically defined herein, the use of all commercially available products herein employs standard techniques. For example, it may be carried out using the manufacturer's instructions for use with the kit, or in accordance with methods known in the art or the description of this invention. The techniques and methods described herein can generally be implemented according to conventional methods well known in the art, based on the descriptions in the various summary and more specific documents cited and discussed in this specification.

[0018] The “range” disclosed in this document takes the form of a lower limit and an upper limit. It can be one or more lower limits and one or more upper limits, respectively. A given range is defined by selecting a lower limit and an upper limit. The selected lower and upper limits define the boundaries of the particular range. All ranges that can be defined in this way are inclusive and composable; that is, any lower limit can be combined with any upper limit to form a range. For example, if ranges of 60-120 and 80-110 are listed for a specific parameter, it is also expected that ranges of 60-110 and 80-120 are also expected. Furthermore, if the minimum range values ​​are listed as 1 and 2, and if the maximum ranges are listed as 3, 4, and 5, then the following ranges are all expected: 1-2, 1-4, 1-5, 2-3, 2-4, and 2-5.

[0019] In this invention, unless otherwise specified, the numerical range "ab" represents a shortened representation of any combination of real numbers from a to b, where a and b are both real numbers. For example, the numerical range "0-5" means that all real numbers between "0-5" have been listed in this document, and "0-5" is simply a shortened representation of these numerical combinations.

[0020] The term "galactomannan (PHGG)" used in this article refers to a water-soluble polysaccharide mainly composed of a mannose backbone and galactose side chains. It is usually obtained by partial hydrolysis of guar gum. The mannose units are linked by β-1,4-glycosidic bonds to form the backbone, and the galactose units are grafted onto the backbone by α-1,6-glycosidic bonds. It is a water-soluble dietary fiber that can be fermented and utilized by gut microbiota as a prebiotic.

[0021] The term "resistant dextrin" as used in this article refers to water-soluble dietary fiber prepared from edible starch through acid-heat dextrinization. It is a common food ingredient that can resist digestion in the human small intestine, enter the colon for fermentation to produce short-chain fatty acids, and has good water solubility and processing stability.

[0022] The term "guar gum" used in this article refers to a natural polysaccharide extracted from guar bean endosperm. It is a high molecular weight galactomannan with a main chain of β-1,4-D-mannose and a side chain of α-1,6-D-galactose. It can partially swell in cold water and fully dissolve in hot water. It has high viscosity and can be hydrolyzed and chemically modified to obtain modified guar gum derivatives.

[0023] The term "water-soluble dietary fiber" used in this article refers to a type of dietary fiber component that is plant-derived or artificially modified and cannot be digested and absorbed by the human small intestine. It is soluble in water and can be fermented by intestinal microorganisms in the large intestine. It includes soluble polysaccharides, oligosaccharides, etc., and can regulate the intestinal environment. Typical examples include galactomannan, inulin, and pectin.

[0024] The term "short-chain fatty acids" used in this article refers to saturated fatty acids with 2-6 carbon atoms, mainly produced by the fermentation of dietary fiber, prebiotics and other carbohydrates by gut microbiota. These mainly include acetic acid, propionic acid and butyric acid, and can participate in colon energy supply, regulate intestinal barrier function and the body's immunity.

[0025] The term "insoluble fiber" used in this article refers to dietary fiber components that are insoluble in water, are not easily digested and absorbed by the human small intestine, are less likely to be fermented by intestinal flora, and mainly play a role in increasing fecal volume and promoting intestinal peristalsis. It mainly includes cellulose, some hemicellulose, lignin, etc.

[0026] The term "prebiotic" as used in this article refers to a class of substrates that cannot be digested and absorbed by the host, but can selectively stimulate the growth and activity of one or more beneficial bacteria in the gut, thereby producing beneficial physiological effects on the host. Common examples include various functional oligosaccharides and some water-soluble polysaccharides.

[0027] The term "high-concentration liquid preparation" as used in this article refers to a liquid preparation with a liquid dosage form matrix, an active ingredient (prebiotics / dietary fiber) mass fraction of ≥40%, and a system that is an aqueous solution or a water-polyol mixture. It is characterized by high solid content and low water activity, and is different from ordinary diluted oral liquids.

[0028] The term "degree of polymerization (DP)" as used herein refers to the average number of monosaccharide residues contained in a polysaccharide or oligosaccharide molecular chain; it is divided into number-average degree of polymerization (DPn) and weight-average degree of polymerization (DPw). Unless otherwise specified in this application, the degree of polymerization (DP) refers to the weight-average degree of polymerization, which is determined by gel permeation chromatography-refractive index detection (GPC-RID) and is used to characterize the chain length of sugar molecules.

[0029] In a first aspect, the present invention provides a composition for improving intestinal function, comprising galactomannan (PHGG) and resistant dextrin.

[0030] In some specific embodiments, the galactomannan is partially hydrolyzed guar gum with a weight-average molecular weight of 8000 Da to 80000 Da, such as 8000 Da, 15000 Da, 25000 Da, 35000 Da, 45000 Da, 55000 Da, 65000 Da, 75000 Da, 80000 Da, or any range derived therefrom; Preferably, the weight-average molecular weight of the galactomannan is 10,000 Da-60,000 Da; More preferably, the weight-average molecular weight of the galactomannan is 20,000 Da.

[0031] In some specific embodiments, the mass ratio of PHGG to resistant dextrin in the composition is 1-6.5:3-8, for example 1:1, 1:3, 1.5:3.5, 2:4, 2.5:4.5, 3:5, 3.5:5.5, 4:6, 4.5:6.5, 5:7, 5.5:7.2, 6:7.6, 6.5:8, or any subrange or range derived therefrom; Preferably, the mass ratio of PHGG to resistant dextrin in the composition is 2-6:6-8; More preferably, the mass ratio of PHGG to resistant dextrin in the composition is 3.5:6.5.

[0032] Secondly, the present invention provides a method for preparing the composition, comprising the step of mixing the components to obtain the final product.

[0033] In some specific embodiments, the mixing step is further included by granulating PHGG. Preferably, the granulation method is selected from one or more combinations of dry granulation and wet granulation; More preferably, the wet granulation method includes at least one of fluidized bed granulation and high-speed stirring granulation.

[0034] Specifically, the purpose of granulation is to increase the particle size of PHGG and disrupt its aggregated structure.

[0035] In some specific embodiments, the mixing method includes at least one of a paddle mixer, an airflow mixer, a three-dimensional motion mixer, a V-type mixer, and a double cone mixer; The mixing time is 5-60 min, for example 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min, 60 min, or any range derived therefrom.

[0036] Specifically, the composition obtained by the above preparation method has PHGG particles that are fully encapsulated and isolated after granulation, which significantly improves the dispersibility in water or other solvents, effectively prevents agglomeration, and accelerates the dissolution rate.

[0037] Thirdly, the present invention provides the use of the composition in the preparation of products that improve intestinal function.

[0038] In some specific implementations, the product includes food, health products, or pharmaceuticals.

[0039] In some specific embodiments, the dosage form of the product includes liquid, solid powder, granules, tablets, capsules, or semi-solid dosage forms; Specifically, the liquid agent is a high-concentration liquid agent; Specifically, the semi-solid agent includes a gelling agent.

[0040] In some specific implementations, the improvement of intestinal function includes: regulating the intestinal flora, promoting the proliferation of probiotics (Bifidobacteria, Lactobacillus, etc.), and inhibiting the growth of harmful bacteria; improving diarrhea symptoms, especially enteral nutrition-related diarrhea; or relieving constipation symptoms, increasing defecation frequency, and softening stool.

[0041] Fourthly, the present invention provides: a product for improving intestinal function, the raw materials of which include the composition and acceptable excipients.

[0042] In some specific implementations, the product includes food, health products, or pharmaceuticals.

[0043] In some specific embodiments, the dosage form of the product includes liquid, solid powder, granules, tablets, capsules, or semi-solid dosage forms; Specifically, the liquid agent is a high-concentration liquid agent; Specifically, the semi-solid agent includes a gelling agent.

[0044] In some specific embodiments, the acceptable excipients include one or more of acidity regulators, fillers, binders, lubricants, thickeners, flavoring agents, and anti-caking agents.

[0045] The statement that "the mass ratio of PHGG to resistant dextrin in the composition is 1-6.5:3-8" is a generalization derived from the foregoing explanation and / or the following statements in Example 1 ("the raw material composition is specifically PHGG and resistant dextrin in a mass ratio of 3.5:6.5"), Example 2 ("the raw material composition is specifically PHGG and resistant dextrin in a mass ratio of 1:3"), and Example 3 ("the raw material composition is specifically PHGG and resistant dextrin in a mass ratio of 6.5:8"). Therefore, those skilled in the art can reasonably infer that "the mass ratio of PHGG to resistant dextrin in the composition is 1-6.5:3-8," its subordinate concepts, its essentially equivalent technical means, and technical means that can replace it within the scope of conventional and common knowledge based on the existing technical level, should all fall within the protection scope of this invention.

[0046] The beneficial effects of this invention are as follows: The present invention has at least the following beneficial effects: (1) Synergistic effect: This invention is the first to combine PHGG and resistant dextrin in any proportion. PHGG focuses on high fermentability and produces SCFAs to regulate the gut microbiota; resistant dextrin focuses on physical regulation of intestinal contents (moisture and volume). The combination of the two achieves dual intervention on intestinal microecology (microbiota regulation) and intestinal physiological function (moisture and volume regulation), producing a synergistic effect of "1+1>2", which can more effectively regulate intestinal function in both directions and improve diarrhea and constipation.

[0047] (2) High safety and wide applicability: The raw materials used in the composition of this invention are all fully soluble dietary fiber, which avoids the risk of intestinal obstruction that may be caused by insoluble fiber to critically ill patients, and has high safety. It can be widely used in the fields of food, health food and pharmaceuticals, and is suitable for all kinds of people, especially those with weak intestinal function (such as the elderly, postoperative patients and critically ill patients).

[0048] (3) Simple process and easy to industrialize: The preparation method of the present invention has simple steps, no need for complex equipment, controllable operation, and stable product quality, which is very suitable for large-scale industrial production.

[0049] (4) Diverse application forms: The composition of the present invention can be processed into various dosage forms such as liquid, solid (powder, granules, tablets, capsules), and semi-solid as needed to meet the needs of different application scenarios.

[0050] Furthermore, based on the present invention: 1. Based on the comparison of Examples 1-3 and Comparative Examples 3-4, this invention utilizes a combination of PHGG and resistant dextrin to achieve new technical effects, synergistically regulating intestinal flora and improving defecation indicators in constipated individuals. The combined effect is superior to the sum of the effects of using PHGG or resistant dextrin alone, producing a synergistic effect of 1+1>2. Animal constipation model experiments show that the compound composition significantly improves small intestinal propulsion rate and reduces colonic Mankin injury scores compared to single ingredients; human trials further confirm that the compound composition can significantly increase the frequency of spontaneous defecation and improve stool characteristics in subjects with chronic constipation, with effects superior to dietary fiber alone.

[0051] 2. Based on the comparison of Examples 1-3 and Comparative Examples 1-2, the present invention purposefully selects a specific narrow range of PHGG and resistant dextrin ratios not mentioned in the prior art from the wide range of dietary fiber compound formulations disclosed in the prior art, and achieves unexpected technical effects: within this specific ratio range, it plays a role in multiple dimensions such as intestinal flora regulation, improvement of defecation difficulty, and maintenance of intestinal barrier. Detailed Implementation

[0052] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.

[0053] The present invention will be further described below by way of specific embodiments. Unless otherwise specified, all instruments, devices, equipment, reagents, products, etc., used in the embodiments of the present invention are obtained through conventional commercial means.

[0054] Specific raw material information is shown in Table 1: Table 1. Raw Material Information

[0055] Example 1 A composition for improving intestinal function, wherein the raw materials are PHGG and resistant dextrin in a mass ratio of 3.5:6.5; The specific steps of the preparation method of the composition are as follows: PHGG raw material was granulated using a dry granulator and passed through a 40-mesh sieve to obtain PHGG granules. The PHGG granules and resistant dextrin were then fed into a three-dimensional motion mixer and mixed for 30 minutes. Samples were taken to test the mixing uniformity. The mixture was then discharged, packaged, and the final composition was obtained.

[0056] Example 2 A composition for improving intestinal function and regulating immunity, wherein the raw materials are PHGG and resistant dextrin in a mass ratio of 1:3; The specific steps of the preparation method of the composition are as follows: Take PHGG raw material, add an appropriate amount of purified water as a wetting agent, granulate using a fluidized bed granulator, dry, and granulate to obtain PHGG granules. Add the PHGG granules and resistant dextrin together into a V-type mixer, mix for 45 minutes, and then sample to test the mixing uniformity. Discharge, package, and obtain the composition.

[0057] Example 3 Compared with Example 1, the only difference is that the raw material composition is PHGG and resistant dextrin in a mass ratio of 6.5:8, and the other conditions are basically the same as in Example 1.

[0058] Example 4 A product (tablet) for improving intestinal function, wherein the components are the composition obtained in Example 1 and microcrystalline cellulose (as a filler) and magnesium stearate (as a lubricant). The above components are mixed and then pressed to obtain the final product.

[0059] The specific preparation process is as follows: The formulation for 1000 tablets by weight is as follows: 200.0 g of the composition obtained in Example 1, 75.0 g of microcrystalline cellulose (PH102, filler), and 3.0 g of magnesium stearate (lubricant); Preparation process: The above raw materials are sieved and dried for pretreatment, and the moisture content of the materials is controlled to be ≤5.0%. The composition obtained in Example 1 and microcrystalline cellulose are put into a three-dimensional motion mixer and premixed at 12 r / min for 15 min. Then magnesium stearate is added and mixed for 3 min. The resulting mixed powder is pressed into tablets using a rotary tablet press and a Φ8 mm circular flat punch under a pressure of 6-8 kN. The tablet hardness is controlled to be 4-6 kgf and the friability is <1.0%. After passing the tests for tablet weight difference, disintegration time and other indicators, the tablets are sealed in aluminum-plastic blister packs to avoid light, and the product - tablets - is obtained.

[0060] Example 5 Compared with Example 4, the only difference is that "the composition obtained in Example 1" is replaced with "the composition obtained in Example 2", and the other conditions are basically the same as those in Example 4.

[0061] Example 6 Compared with Example 4, the only difference is that "the composition obtained in Example 1" is replaced with "the composition obtained in Example 3", and the other conditions are basically the same as those in Example 4.

[0062] Comparative Example 1 Compared with Example 1, the only difference is that the raw material composition is PHGG and resistant dextrin in a mass ratio of 3.5:1, and the other conditions are basically the same as in Example 1.

[0063] Comparative Example 2 Compared with Example 1, the only difference is that the raw material composition is PHGG and resistant dextrin in a mass ratio of 0.5:8.5, and the other conditions are basically the same as in Example 1.

[0064] Comparative Example 3 Compared with Example 1, the only difference is that "resistant dextrin" is replaced with "maltodextrin" and "PHGG" is replaced with "inulin". The other conditions are basically the same as in Example 1.

[0065] The specific preparation steps are as follows: Inulin raw material was granulated using a dry granulator and passed through a 40-mesh sieve to obtain inulin granules. These inulin granules were then added together with maltodextrin into a three-dimensional motion mixer and mixed for 30 minutes. Samples were taken to test the mixing uniformity. The mixture was then discharged, packaged, and the final composition was obtained. Comparative Example 4 Compared with Example 1, the only difference is that the raw material composition is PHGG, resistant dextrin, stachyose and lactitol in a mass ratio of 3.5:6.5:2:2, and the other conditions are basically the same as in Example 1.

[0066] The specific steps of the preparation method of the composition are as follows: PHGG raw material was granulated using a dry granulator and passed through a 40-mesh sieve to obtain PHGG granules. These PHGG granules were then added to a three-dimensional motion mixer along with resistant dextrin, stachyose, and lactitol. The mixture was mixed for 30 minutes, and samples were taken to test the uniformity of the mixture. The mixture was then discharged, packaged, and the final composition was obtained.

[0067] Example 1: Mouse animal model experiment (1) Experimental animals: SPF-grade C57BL / 6 healthy mice, half male and half female, weighing 18-22g, were selected and acclimatized for 7 days before being used in the experiment. They were randomly divided into 14 groups of 10 mice each. The housing environment was as follows: temperature 22±2℃, relative humidity 50%±10%, with a 12-hour light-dark cycle. The mice had free access to food and water.

[0068] (2) Constipation model creation method: A functional constipation model was induced in mice using loperamide hydrochloride. Loperamide hydrochloride was dissolved in sterile distilled water and administered orally at a dose of 5 mg / kg body weight once daily for 5 consecutive days. Successful modeling was determined by a significant prolongation of the time to first black feces, a significant reduction in the number of feces excreted within 6 hours, and a significant decrease in fecal water content. Mice that failed the modeling test were excluded before proceeding to the formal drug administration experiment. The blank control group mice were administered an equal volume of physiological saline by gavage throughout the entire process and did not undergo any modeling treatment.

[0069] (3) The specific grouping and administration details are as follows: Blank control group: Normal basal feed, administered by gavage with an equal volume of physiological saline; Model control group: Constipation model was established, and the same volume of physiological saline was administered by gavage; Positive control group: Constipation model was established, and lactulose, a clinical laxative, was administered by gavage at a dose of 200 mg / kg·d; Single PHGG group: Constipation model established, galactomannan 200 mg / kg administered by gavage. d; Single resistant dextrin group: constipation model established, resistant dextrin 200 mg / kg administered by gavage. d; Low-dose group of the composition obtained in Example 1 of this invention: constipation model was established, and the composition obtained in Example 1 was administered by gavage at a dose of 100 mg / kg. d; Dosage group of the composition obtained in Example 1 of this invention: constipation model established, 200 mg / kg of the composition obtained in Example 1 administered by gavage. d; High-dose group of the composition obtained in Example 1 of this invention: constipation model was established, and the composition obtained in Example 1 was administered by gavage at a dose of 400 mg / kg. d; The composition obtained in Example 2 of this invention: constipation model was established, and the composition obtained in Example 2 was administered by gavage at a dose of 200 mg / kg. d; The composition obtained in Example 3 of this invention: constipation model was established, and the composition obtained in Example 3 was administered by gavage at a dose of 200 mg / kg. d; The composition obtained in Comparative Example 1 of this invention: constipation model was established, and the composition obtained in Comparative Example 1 was administered by gavage at a dose of 200 mg / kg. d; The composition obtained in Comparative Example 2 of this invention: constipation model was established, and the composition obtained in Comparative Example 2 was administered by gavage at a dose of 200 mg / kg. d; The composition obtained in Comparative Example 3 of this invention: constipation model was established, and the composition obtained in Comparative Example 3 was administered by gavage at a dose of 200 mg / kg. d; The composition obtained in Comparative Example 4 of this invention: constipation model was established, and the composition obtained in Comparative Example 4 was administered by gavage at a dose of 200 mg / kg. d; The dosage is uniform: 10 mL / kg body weight; administered by gavage once daily for 7 consecutive days.

[0070] (4) Detection indicators: ① Fecal moisture content (%): Collect fresh mouse feces and accurately weigh the wet weight (W). 湿 The feces were dried in a 105°C oven until constant weight, and the dry weight (W) was measured. 干 ), calculate according to the formula Fecal moisture content (%) = (W 湿 -W 干 ) / W 湿 100%; W 湿 : Fresh fecal wet weight (g); W 干 Dry weight (g) of feces after drying at 105℃ to constant weight; ② 6-hour fecal pellet count: After administering the test substance to the model mice, they were placed in separate metabolic cages, and all fecal pellets excreted within 0-6 hours after administration were continuously collected. The total number of fecal pellets was counted manually, which is the 6-hour fecal pellet count.

[0071] ③ Time of first black feces excretion: After the last administration, all mice were given an equal volume of 5% carbon dioxide suspension by gavage. The timing was immediately recorded, and the time when each mouse excreted the first black feces was closely observed and recorded. ④ Small intestinal propulsion rate: Mice were given a carbon suspension by gavage after the last administration, sacrificed 30 minutes later, dissected and removed from the small intestine, and the distance the carbon was propulsed in the small intestine was measured and the total length of the small intestine was measured and substituted into the formula for calculation. Small intestinal propulsion rate (%) = (distance from ink tip to pylorus / total length of small intestine from pylorus to ileocecal junction) 100%; ⑤ Colon Mankin histology score; Table 2. Mankin Histological Scoring Criteria for Colon (Colonal Mucosal Injury, Total Score 0-12)

[0072] Note: Scoring method: Total score = Epithelial structure score + Inflammatory cell infiltration score + Crypt morphology change score + Mucosal edema and fibrosis score; The breakdown is as follows: 0 points: normal colonic mucosal tissue morphology; 1-4 points: mild mucosal damage; 5-9 points: moderate mucosal damage; 10-12 points: severe mucosal damage.

[0073] Statistics: One-way ANOVA was performed using SPSS, and P < 0.05 was considered statistically significant between groups.

[0074] (5) Test results The test results are shown below: Table 3

[0075] Note: : Compared with the blank control group, P < 0.05; #: Compared with the model control group, P < 0.05; ##: Compared with the model control group, P < 0.01; ###: Compared with the model control group, P < 0.001; △: Compared with the dose group in Example 1, P < 0.05; △△: Compared with the dose group in Example 1, P < 0.01.

[0076] The PHGG and resistant dextrin-blocked binary composition of this invention can synergistically improve the defecation ability of constipated mice, increase fecal water content, accelerate intestinal transit, and reduce colonic mucosal damage. The laxative effect is significantly dose-dependent. The laxative effect can be achieved within the limited ratio range. Exceeding the range, replacing the active ingredient, or adding additional ingredients will significantly reduce the synergistic effect. In Example 1, the optimal ratio at medium and high doses showed excellent laxative and intestinal mucosal protection effects.

[0077] The effect of Example 2 on the regulation of mouse gut microbiota structure and short-chain fatty acids (SCFAs) was investigated. This experiment, based on the aforementioned constipation model mice, explores the regulatory effects of the composition of the present invention on intestinal microecology and metabolites, verifies the synergistic effect of PHGG and resistant dextrin on gut microbiota regulation and short-chain fatty acid synthesis, and further elucidates the mechanism by which the composition improves intestinal health.

[0078] (1) Test samples and grouping The experimental animals, modeling methods, grouping methods, drug dosages and cycles were completely consistent with those of Case 1, ensuring a unified experimental system and comparable data.

[0079] (2) Sample collection and testing methods After 7 days of continuous administration, fresh feces from mice in each group were aseptically collected, placed in sterile cryovials, flash-frozen in liquid nitrogen, and stored at -80°C.

[0080] The content of core short-chain fatty acids (acetic acid, propionic acid, and butyric acid) in feces was determined by gas chromatography (GC).

[0081] (3) Experimental results and analysis Table 4

[0082] Note: : Compared with the blank control group, P < 0.05; #: Compared with the model control group, P < 0.05; ##: Compared with the model control group, P < 0.01; ###: Compared with the model control group, P < 0.001; △: Compared with the dose group in Example 1, P < 0.05; △△: Compared with the dose group in Example 1, P < 0.01; △△△: Compared with the dose group in Example 1, P < 0.001.

[0083] The PHGG and resistant dextrin binary composition of the present invention can synergistically promote the production of acetic acid, propionic acid, and especially butyric acid, and the efficacy is dose-dependent; this synergistic effect can only be achieved within the specified ratio range of the present invention; changing the ratio, replacing the core component, or adding additional components will all result in a significant decrease in the effect of microbial regulation and short-chain fatty acid enhancement.

[0084] Example 3: Human Food Trial This test case uses a human trial to evaluate the regulatory effect of the solid beverages prepared in Examples 4-6 on human intestinal function.

[0085] (1) Test sample Placebo (maltodextrin): Appearance, taste, and packaging are identical to the test sample; does not contain PHGG or resistant dextrin active ingredients. Intervention group: Solid beverage products prepared using Examples 4, 5, and 6 of this invention as active ingredients.

[0086] (2) Inclusion and exclusion criteria for subjects Inclusion criteria: participants aged 25-65 years with chronic constipation who meet the following criteria: spontaneous bowel movements <3 times per week, stool consistency Bristol score ≤2 for ≥4 weeks; and who voluntarily participate and sign informed consent form.

[0087] Exclusion criteria: severe organic gastrointestinal diseases, abnormal liver and kidney function; taking probiotics, laxatives, or dietary fiber supplements within 30 days prior to the test; pregnancy or lactation; allergic constitution; unable to cooperate in completing the test.

[0088] (3) Experimental design A randomized, double-blind, placebo-controlled trial was conducted. Participants were randomly assigned to four groups: the placebo group, Example 4 group, Example 5 group, and Example 6 group, with 40 participants in each group.

[0089] Dosage: Take 1 sachet once a day (total dose of active ingredients 10g / day), dissolved in warm water, for 30 consecutive days; maintain your original diet and lifestyle during the trial period, and avoid additional intake of dietary fiber and laxative products.

[0090] (4) Observation indicators ① Number of spontaneous bowel movements per week; ② Stool Bristol Characteristics Score (1-7 points, the higher the score, the softer the stool); The specific scoring criteria are as follows; Table 5

[0091] ③ Score for difficulty in defecation (0-3 points, 0 = no effort, 3 = extremely difficult defecation); the specific scoring criteria are as follows: Table 6

[0092] Statistical methods: SPSS 26.0 software was used for statistical analysis. Quantitative data were expressed as mean ± standard deviation. Paired t-tests were performed within groups before and after intervention. One-way ANOVA was used for comparisons between groups. P < 0.05 was considered statistically significant.

[0093] Significance marking: Compared with 0d, the difference in the same group at 28d was P<0.05; compared with the placebo group at 28d, the difference was P<0.05.

[0094] (3) Test results The measured results are shown below: Table 7

[0095] Significance marking: Compared with 0d, the difference in the same group at 28d was P<0.05; compared with the placebo group at 28d, the difference was P<0.05.

[0096] At day 0 of the trial, there were no significant differences in the number of spontaneous bowel movements per week, Bristol defecation scores, and defecation effort scores among the placebo group and subjects in Examples 4-6 (P > 0.05). The baseline levels of each group were consistent and comparable.

[0097] After 28 days of continuous administration of the placebo group, there were no statistically significant differences in any indicators compared to day 0 (P > 0.05), indicating that the placebo had no significant effect on improving bowel movements in the subjects. In Examples 4-6, after 28 days of administration of the sample, subjects showed a significant increase in the frequency of spontaneous bowel movements per week, an increase in the Bristol defecation score, and a significant decrease in the defecation effort score; these differences were statistically significant compared to day 0. (P < 0.05); compared with the placebo group at 28 days, the differences in the above indicators were also statistically significant (#P < 0.05). This indicates that the optimal ratio of PHGG and resistant dextrin in this invention has a stronger synergistic effect in improving defecation indicators in people with chronic constipation.

[0098] A 28-day human trial has confirmed that the solid beverage prepared from the PHGG and resistant dextrin composition of this invention can effectively increase the frequency of spontaneous bowel movements per week in people with chronic constipation, soften stools, reduce the difficulty of defecation, and has a good regulatory effect on human intestinal function.

[0099] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A composition for improving intestinal function, characterized in that, It is composed of galactomannan and resistant dextrin.

2. The composition according to claim 1, characterized in that, The galactomannan is partially hydrolyzed guar gum with a weight-average molecular weight of 8000 Da-80000 Da.

3. The composition according to claim 2, characterized in that, The weight-average molecular weight of the galactomannan is 10,000 Da to 60,000 Da.

4. The composition according to claim 1, characterized in that, The mass ratio of galactomannan to resistant dextrin in the composition is 1-6.5:3-8.

5. The composition according to claim 4, characterized in that, The mass ratio of galactomannan to resistant dextrin in the composition is 3.5:6.

5.

6. A method for preparing the composition according to any one of claims 1-5, characterized in that, The process includes the following steps: mixing galactomannan and resistant dextrin to obtain the final product.

7. The preparation method according to claim 6, characterized in that, The mixing step is preceded by a step of granulating galactomannan; The granulation method is selected from one or more combinations of dry granulation and wet granulation; The mixing method includes at least one of the following: paddle mixer, airflow mixer, three-dimensional motion mixer, V-type mixer, and double cone mixer; The mixing time is 5-60 minutes.

8. Use of the composition according to any one of claims 1-5 in the preparation of products that improve intestinal function.

9. A product for improving intestinal function, characterized in that, The raw materials include the composition according to any one of claims 1-5 and acceptable excipients.

10. The product according to claim 9, characterized in that, The dosage forms of the product include liquid, solid powder, granules, tablets, capsules, or semi-solid dosage forms; The acceptable excipients include one or more of the following: acidity regulators, fillers, binders, lubricants, thickeners, flavoring agents, and anti-caking agents.

Citation Information

Patent Citations

  • Dietary fiber composition and application thereof

    CN116473243A

  • Galactomannan synergistic immune regulation type prebiotic syrup

    CN121337013A

  • Composition of plant extract capable of taking effect quickly and probiotics with long-term effect and application of composition

    CN121621519A

  • Prebiotics formula and preparation method

    CN122140755A

  • Stachyose strontium-rich water composition for conditioning intestinal flora balance and preparation method thereof

    CN122536689A